secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2022-05-20T23:59:59+00:00
Accession:  0001104659-22-063262
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics stockholders approve 2.6M share increase to equity incentive plan
-------------------------------------------------------------------------------

- Stockholders approved amendment to 2013 Equity Incentive Plan, increasing share reserve by 2,619,622 shares.
- All three director nominees (Scott Jackson, Scott Koenig, Harout Semerjian) were elected.
- Ratification of Ernst & Young as independent auditor passed with 38,971,830 votes for.
- Advisory vote on executive compensation approved with 27,132,991 votes for.
- Annual meeting had 75% of shares present or represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000110465922063262/0001104659-22-063262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000110465922063262/tm2216126d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-063262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer